These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

589 related items for PubMed ID: 15203413

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes.
    Palepu A, Tyndall MW, Chan K, Wood E, Montaner JS, Hogg RS.
    Antivir Ther; 2004 Oct; 9(5):713-9. PubMed ID: 15535408
    [Abstract] [Full Text] [Related]

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K.
    Verh K Acad Geneeskd Belg; 2001 Oct; 63(5):447-73. PubMed ID: 11813503
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Short communication. Association of the CCR5delta32 mutation with clinical response and >5-year survival following initiation of first triple antiretroviral regimen.
    Brumme ZL, Henrick BM, Brumme CJ, Hogg RS, Montaner JS, Harrigan PR.
    Antivir Ther; 2005 Oct; 10(7):849-53. PubMed ID: 16312181
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.
    Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.
    BMC Pediatr; 2007 Mar 17; 7():13. PubMed ID: 17367540
    [Abstract] [Full Text] [Related]

  • 10. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users.
    Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, Hogg RS.
    CMAJ; 2003 Sep 30; 169(7):656-61. PubMed ID: 14517122
    [Abstract] [Full Text] [Related]

  • 11. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
    Aziz N, Sokoloff A, Kornak J, Leva NV, Mendiola ML, Levison J, Feakins C, Shannon M, Cohan D.
    BJOG; 2013 Nov 30; 120(12):1534-47. PubMed ID: 23924192
    [Abstract] [Full Text] [Related]

  • 12. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response.
    Moore DM, Hogg RS, Chan K, Tyndall M, Yip B, Montaner JS.
    AIDS; 2006 Feb 14; 20(3):371-7. PubMed ID: 16439870
    [Abstract] [Full Text] [Related]

  • 13. Determinants of clinical progression in antiretroviral-naive HIV-infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996-2002.
    Bonnet F, Thiébaut R, Chêne G, Neau D, Pellegrin JL, Mercié P, Beylot J, Dabis F, Salamon R, Morlat P, Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA).
    HIV Med; 2005 May 14; 6(3):198-205. PubMed ID: 15876287
    [Abstract] [Full Text] [Related]

  • 14. Regimen-dependent variations in adherence to therapy and virological suppression in patients initiating protease inhibitor-based highly active antiretroviral therapy.
    Moore DM, Hogg RS, Yip B, Wood E, Harris M, Montaner JS.
    HIV Med; 2006 Jul 14; 7(5):311-6. PubMed ID: 16945076
    [Abstract] [Full Text] [Related]

  • 15. Greater adherence to highly active antiretroviral therapy (HAART) between pregnant versus non-pregnant women living with HIV.
    Zorrilla CD, Santiago LE, Knubson D, Liberatore K, Estronza G, Colón O, Acevedo M.
    Cell Mol Biol (Noisy-le-grand); 2003 Dec 14; 49(8):1187-92. PubMed ID: 14983985
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Immunological and virological responses to highly active antiretroviral therapy in a non-clinical trial setting in a developing Caribbean country.
    Kilaru KR, Kumar A, Sippy N, Carter AO, Roach TC.
    HIV Med; 2006 Mar 14; 7(2):99-104. PubMed ID: 16420254
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.
    Moreno A, Perez-Elías MJ, Casado JL, Muñoz V, Antela A, Dronda F, Navas E, Fortún J, Quereda C, Moreno S.
    Antivir Ther; 2000 Dec 14; 5(4):243-8. PubMed ID: 11142618
    [Abstract] [Full Text] [Related]

  • 19. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
    Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ.
    HIV Med; 2007 Jul 14; 8(5):267-70. PubMed ID: 17561871
    [Abstract] [Full Text] [Related]

  • 20. Impact of an adherence clinic on behavioral outcomes and virologic response in treatment of HIV infection: a prospective, randomized, controlled pilot study.
    Rathbun RC, Farmer KC, Stephens JR, Lockhart SM.
    Clin Ther; 2005 Feb 14; 27(2):199-209. PubMed ID: 15811483
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.